Marianne Yood, DSc
Adjunct Research Associate Professor
Boston University School of Public Health
Dept of Epidemiology

MPH, Boston University School of Public Health
DSc, Boston University School of Public Health



Dr. Ulcickas Yood has more than 25 years professional experience in epidemiologic research. Her research focuses on pharmacoepidemiology and drug safety as well as methodologic issues relating to exposure measurement and data quality in large administrative databases. She collaborates with the Cancer Research Network to study cancer treatment effectiveness and sequelae. Dr. Ulcickas Yood has served on various advisory boards related to pharmacoepidemiology and drug safety and is currently a member of the Editorial Board for Pharmacoepidemiology and Drug Safety. She has published over 75 articles in numerous journals and is currently a co-investigator on 6 NIH funded grants. In addition, Dr. Ulcickas Yood is principal epidemiologist at EpiSource, an organization that designs and implements pharmacoepidemiology studies.

2011 International Society for Pharmacoepidemiology: Fellow
1999 Bristol-Myers Squibb: Excellence Award
1995 Society for Epidemiologic Research: Student Workshop on Epidemiologic Methods
1995 American Society for Preventive Oncology: New Investigators Workshop
1990 US Public Health Service: Achievement Medal
1990 US Public Health Service: Citation
1986 Boston University: Dean's Citation for Student Leadership


OUTCOMES OF PROSTATE CANCER ANDROGEN DEPRIVATION THERAPY
04/02/2010 - 07/31/2014 (PI)
Henry Ford Health System NIH NCI
5R01CA014294-03

STATINS & LYMPHOID MALIGNANCY RISK IN A LARGE MULTI-SITE POPULATION-BASED COHORT
04/01/2010 - 04/30/2014 (PI)
Henry Ford Health System NIH NCI
R01CA140754-04

LONG-TERM SURVIVORSHIP IN OLDER WOMEN WITH EARLY STAGE BREAST CANCER
10/01/2009 - 07/31/2013 (PI)
Boston Medical Center Corporation NIH NCI
5R01CA093772-08




Yr Title Project-Sub Proj Pubs
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

  1. Bradley MC, Zhou Y, Freedman AN, Yood MU, Quesenbery CP, Haque R, Van Den Eeden SK, Cassidy-Bushrow AE, Aaronson D, Potosky AL. Risk of diabetes complications among those with diabetes receiving androgen deprivation therapy for localized prostate cancer. Cancer Causes Control. 2018 Aug; 29(8):785-791. PMID: 29959604.
     
  2. Alford SH, Divine G, Chao C, Habel LA, Janakiraman N, Wang Y, Feigelson HS, Scholes D, Roblin D, Epstein MM, Engel L, Havstad S, Wells K, Yood MU, Fortuny J, Johnson CC. Serum cholesterol trajectories in the 10 years prior to lymphoma diagnosis. Cancer Causes Control. 2018 Jan; 29(1):143-156. PMID: 29192350.
     
  3. Johnson CC, Jankowski M, Rolnick S, Yood MU, Alford SH. Influence of NSAID Use Among Colorectal Cancer Survivors on Cancer Outcomes. Am J Clin Oncol. 2017 Aug; 40(4):370-374. PMID: 25503426.
     
  4. Epstein MM, Divine G, Chao CR, Wells KE, Feigelson HS, Scholes D, Roblin D, Ulcickas Yood M, Engel LS, Taylor A, Fortuny J, Habel LA, Johnson CC. Statin use and risk of multiple myeloma: An analysis from the cancer research network. Int J Cancer. 2017 Aug 01; 141(3):480-487. PMID: 28425616; DOI: 10.1002/ijc.30745;.
     
  5. Fu AZ, Tsai HT, Haque R, Yood MU, Cassidy-Bushrow AE, Van Den Eeden SK, Keating NL, Smith MR, Zhou Y, Aaronson DS, Potosky AL. Mortality and Androgen Deprivation Therapy as Salvage Treatment for Biochemical Recurrence after Primary Therapy for Clinically Localized Prostate Cancer. J Urol. 2017 Jun; 197(6):1448-1454. PMID: 28007467.
     
  6. Fu AZ, Tsai HT, Haque R, Ulcickas Yood M, Van Den Eeden SK, Cassidy-Bushrow AE, Zhou Y, Keating NL, Smith MR, Aaronson DS, Potosky AL. Use of androgen deprivation therapy as salvage treatment after primary therapy for clinically localized prostate cancer. World J Urol. 2016 Dec; 34(12):1611-1619. PMID: 27084777; DOI: 10.1007/s00345-016-1823-5;.
     
  7. Ulcickas Yood M, Bortolini M, Casso D, Beck JG, Oliveria SA, Wells KE, Woodcroft KJ, Wang LI. Incidence of liver injury among cancer patients receiving chemotherapy in an integrated health system. Pharmacoepidemiol Drug Saf. 2015 Apr; 24(4):427-34. PMID: 25683797; DOI: 10.1002/pds.3757;.
     
  8. Tsai HT, Keating NL, Van Den Eeden SK, Haque R, Cassidy-Bushrow AE, Ulcickas Yood M, Smith MR, Potosky AL. Risk of diabetes among patients receiving primary androgen deprivation therapy for clinically localized prostate cancer. J Urol. 2015 Jun; 193(6):1956-62. PMID: 25524243; DOI: 10.1016/j.juro.2014.12.027;.
     
  9. McGlynn KA, Divine GW, Sahasrabuddhe VV, Engel LS, VanSlooten A, Wells K, Yood MU, Alford SH. Statin use and risk of hepatocellular carcinoma in a U.S. population. Cancer Epidemiol. 2014 Oct; 38(5):523-7. PMID: 25113938; PMCID: PMC4188715; DOI: 10.1016/j.canep.2014.06.009;.
     
  10. Jordan JH, Thwin SS, Lash TL, Buist DS, Field TS, Haque R, Pawloski PA, Petersen HV, Prout MN, Quinn VP, Yood MU, Silliman RA, Geiger AM. Incident comorbidities and all-cause mortality among 5-year survivors of Stage I and II breast cancer diagnosed at age 65 or older: a prospective-matched cohort study. Breast Cancer Res Treat. 2014 Jul; 146(2):401-9.View Related Profiles. PMID: 24939060; PMCID: PMC4506645; DOI: 10.1007/s10549-014-3021-8;.
     
Showing 10 of 104 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 104 publications over 26 distinct years, with a maximum of 17 publications in 2007

YearPublications
19891
19923
19931
19941
19964
19971
19981
19993
20011
20021
20032
20044
20058
200612
200717
20082
20098
20104
20114
20126
20133
201410
20151
20162
20173
20181
Contact for Mentoring:


715 Albany St Talbot Building
Boston MA 02118
Google Map


Yood's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Co-Authors
_
Similar People
_
Same Department